Today: 28 June 2026
Browse Category

TSX:4543 26 August 2025

Billion-Dollar Pharma Deals, Biotech Breakthroughs & Global Health Alerts – Biotech & Health News Roundup (Aug 25–26, 2025)

Billion-Dollar Pharma Deals, Biotech Breakthroughs & Global Health Alerts – Biotech & Health News Roundup (Aug 25–26, 2025)

AbbVie agreed to acquire Gilgamesh Pharmaceuticals’ experimental psychedelic depression drug for up to $1.2 billion, planning to advance it to Phase 3 trials. Japan’s Terumo will buy UK-based OrganOx for $1.5 billion, gaining organ preservation technology. LB Pharma filed for a $100 million IPO, the first biotech IPO in six months. Arnatar Therapeutics raised $52 million to develop RNA therapy for Alagille syndrome.
26 August 2025

Stock Market Today

  • AbraSilver Resource Posts New Diablillos DFS, Stock Valuation Debated
    June 28, 2026, 3:44 PM EDT. AbraSilver Resource (TSX:ABRA) released a new Definitive Feasibility Study (DFS) for its Diablillos project, updating investors on mine plan metrics and reserves. The stock recently traded at CA$14.46, showing volatility with a mix of short-term gains and a 21.5% decline over one month. Analysts note the company's Price to Book (P/B) ratio of 33.9x is low compared to its peer group average of 144.2x, suggesting relative value within early-stage metal exploration. However, this P/B is high against the broader Canadian mining sector average of 2.6x, reflecting market optimism driven by project prospects despite AbraSilver's CA$62.56 million operating losses and reliance on high-risk funding. Investor sentiment remains mixed on whether the stock price fairly accounts for future growth risks and rewards.

Latest articles

Go toTop